• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 3:00:57 PM ET
    $CFMS
    Industrial Specialties
    Health Care
    Get the next $CFMS alert in real time by email
    SC 13G/A 1 d8805050_13g-a.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Conformis, Inc.
    (Name of Issuer)

     

     

    Common Stock, par value $0.00001 per share
    (Title of Class of Securities)

     

     

    20717E101
    (CUSIP Number)

     

     

    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which th9,538,357

    is Schedule is filed:

    [X] Rule 13d-1(b)

     

    [_] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

     


    CUSIP No
    20717E101    

     

         
    1. NAME OF REPORTING PERSONS  
         
      Armistice Capital, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      9,538,357    
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      9,538,357    
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      9,538,357    
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.99%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IA, OO  
     
     

     

    CUSIP No 20717E101    

     

         
    1. NAME OF REPORTING PERSONS  
         
      Steven Boyd  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      9,538,357    
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      9,538,357    
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      9,538,357    
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.99%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IN, HC  
     
     

     


    CUSIP No
    20717E101    

     

           
    Item 1. (a). Name of Issuer:  
           
        Conformis, Inc.  
           
      (b). Address of Issuer's Principal Executive Offices:  
           
       

    600 Technology Park Drive

    Billerica, Massachusetts 01821

    United States of America

     
           
           
    Item 2. (a). Name of Person Filing:  
           
       

    Armistice Capital, LLC

    Steven Boyd

     
           
      (b). Address of Principal Business Office, or if None, Residence:  
           
       

    Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     

    Steven Boyd

    c/o Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     
           
      (c) Citizenship:  
           
       

    Armistice Capital, LLC – Delaware

    Steven Boyd – United States of America

     
           
      (d).   Title of Class of Securities:  
           
        Common Stock, par value $$0.00001 per share  
     

     

     

       
      (e). CUSIP Number:  
           
        20717E101  

     

     
     

     

     

     


    Item 3.
      If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a
           
      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [X] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [X] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

     
     

     

     

     
    Item 4. Ownership.
     
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       
      (a)   Amount beneficially owned:
         
       

    Armistice Capital, LLC – 9,538,357

    Steven Boyd – 9,538,357

         
      (b)   Percent of class:
         
       

    Armistice Capital, LLC – 9.99%

    Steven Boyd – 9.99%

         

     

      (c)   Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote    
         

     

    Armistice Capital, LLC – 0

    Steven Boyd – 0

     

     
        (ii)   Shared power to vote or to direct the vote    
         

     

    Armistice Capital, LLC – 9,538,357

    Steven Boyd – 9,538,357

     

     
        (iii) Sole power to dispose or to direct the disposition of    
         

     

    Armistice Capital, LLC – 0

    Steven Boyd – 0

     

     
        (iv)   Shared power to dispose or to direct the disposition of    
         

     

    Armistice Capital, LLC – 9,538,357

    Steven Boyd – 9,538,357

     
                 

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [_].
       
      N/A

     

     

     
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
       
      Armistice Capital Master Fund Ltd., a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, LLC, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
       

     

     
     

     

     

     

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
       
      If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      N/A
     

     

     

    Item 8. Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      N/A
     

     

     

    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
       
      N/A
     

     

     

    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

     

     

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

      February 16, 2021
      (Date)

     

     

      Armistice Capital, LLC
       
      By:  /s/ Steven Boyd
      Steven Boyd
      Managing Member
     

     

     

      /s/ Steven Boyd
      Steven Boyd

     

     

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     
     

     

    Exhibit A

    AGREEMENT

     

    The undersigned agree that this Amendment No. 1 to Schedule 13G dated February 16, 2021 relating to the Common Stock, par value $$0.00001 per share, of Conformis, Inc. shall be filed on behalf of the undersigned.

      Armistice Capital, LLC
       
      By:  /s/ Steven Boyd
      Steven Boyd
      Managing Member
     

     

     

      /s/ Steven Boyd
      Steven Boyd

     

     

     

     

     

     

     

     

     

     

    Get the next $CFMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CFMS

    DatePrice TargetRatingAnalyst
    11/4/2021$2.50 → $2.00Outperform
    Oppenheimer
    9/22/2021$3.00 → $2.50Outperform
    Oppenheimer
    More analyst ratings

    $CFMS
    Financials

    Live finance-specific insights

    See more
    • Conformis Reports First Quarter 2023 Financial Results

      BILLERICA, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2023. First Quarter 2023 Summary Total revenue of $12.8 million, a decrease of 17% year-over-year on a reported and constant currency basis.Product revenue of $12.7 million, a decrease of 15% year-over-year on a reported basis and 14% on a constant currency basis.Conformis hip system revenue of $0.8 million, an increase of 3% year-over-year.Cash and cash equivalents of $37.8 million as of March 31, 2023.   Three months ended March 31,

      5/8/23 8:05:00 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Conformis, Inc. to Announce Financial Results for Its First Quarter on May 8, 2023

      BILLERICA, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the first quarter ended March 31, 2023, before the market opens on Monday, May 8, 2023. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the financial results and provide a business update. Earnings Call and Webcast Details: The webcast of the earnings call will be live at: Link Directly to Webcast To attend by telephone, please use the information below for dial-in access. Date and Time

      4/13/23 4:30:00 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Conformis, Inc. Reports Fourth Quarter and Year End 2022 Financial Results

      BILLERICA, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the fourth quarter and year ended December 31, 2022. Fourth Quarter 2022 Summary Total revenue of $17.4 million, an increase of 13% year-over-year on a reported basis and 14% on a constant currency basis.Product revenue of $14.2 million, a decrease of 7% year-over-year on a reported basis and 6% on a constant currency basis.Hip system revenue of $0.6 million, a decrease of 15% year-over-year.Cash and cash equivalents of $48.7 million as of December 31, 2022.First procedur

      3/1/23 4:05:00 PM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • restor3d Completes Acquisition of Conformis

      DURHAM, North Carolina and BILLERICA, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- restor3d, Inc. and Conformis, Inc. announced today that restor3d has completed its previously announced acquisition of Conformis following the approval of Conformis' stockholders at a special meeting held on August 31, 2023. In connection with the completion of the acquisition, shares of Conformis' common stock ceased trading on the NASDAQ prior to the opening of the NASDAQ on September 5, 2023. "We are extremely excited to complete this important transaction and look forward to leveraging our combined portfolio to deliver personalized orthopedic solutions for the whole human body," said J. Kurt Jacobus, CEO o

      9/5/23 8:18:31 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Conformis Stockholders Vote "FOR" the Pending Merger with restor3d

      BILLERICA, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co., LLC ("Glass Lewis"), have each recommended that Conformis stockholders vote "FOR" the pending merger transaction with restor3d. As previously announced, under the terms of the definitive merger agreement, restor3d will acquire all outstanding shares of common stock of Conformis for $2.27 per share in an all cash transaction. Conformis is pleased that ISS and Glass Lewis share its be

      8/23/23 8:00:00 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Independent Proxy Advisory Firm ISS Recommends Conformis Stockholders Vote "FOR" the Pending Merger with restor3d

      BILLERICA, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firm, Institutional Shareholder Services Inc. ("ISS"), has recommended that Conformis stockholders vote "FOR" the pending merger transaction with restor3d. As previously announced, under the terms of the definitive merger agreement, restor3d will acquire all outstanding shares of common stock of Conformis for $2.27 per share in an all cash transaction. Conformis is pleased that ISS shares its belief that the proposed merger with restor3d is in the best inte

      8/21/23 4:10:25 PM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Fischetti Gary P returned 10,470 shares to the company, closing all direct ownership in the company

      4 - Conformis Inc (0001305773) (Issuer)

      9/5/23 6:13:51 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form 4: Johnston Philip W returned 19,273 shares to the company, closing all direct ownership in the company

      4 - Conformis Inc (0001305773) (Issuer)

      9/5/23 6:13:47 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form 4: Augusti Mark A was granted 17,778 shares and returned 190,277 shares to the company, closing all direct ownership in the company

      4 - Conformis Inc (0001305773) (Issuer)

      9/5/23 6:13:53 AM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer reiterated coverage on Conformis with a new price target

      Oppenheimer reiterated coverage of Conformis with a rating of Outperform and set a new price target of $2.00 from $2.50 previously

      11/4/21 10:00:09 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Oppenheimer reiterated coverage on Conformis with a new price target

      Oppenheimer reiterated coverage of Conformis with a rating of Outperform and set a new price target of $2.50 from $3.00 previously

      9/22/21 7:20:22 AM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    Leadership Updates

    Live Leadership Updates

    See more
    • Conformis, Inc. Appoints Michael Fillion as Chief Operating Officer

      BILLERICA, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), announced today that Michael Fillion has joined the Company as its Chief Operating Officer. "We are pleased to announce the addition of Michael Fillion as Chief Operating Officer. Mike brings to this role 30 years of experience in manufacturing and operations with a strong focus in precision metal products, medical devices, continuous improvement, and strategic business planning," said Mark Augusti, President and Chief Executive officer. "I look forward to the contributions he will make as a member of the Conformis team." Michael Fillion Prior to joining Conformis, Michael served as the Executive Vice Pr

      4/1/22 5:00:00 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Conformis, Inc. Appoints Denise Pedulla as Chief Legal Officer and Corporate Secretary

      BILLERICA, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Denise Pedulla has joined the Company as its Chief Legal Officer and Corporate Secretary. "We are pleased to announce the addition of Denise Pedulla as Chief Legal Officer and Corporate Secretary. Her strong public company experience and leadership capabilities will help support our growth strategy and further strengthens our executive team," said Mark Augusti, President and Chief Executive Officer. "I look forward to the contributions she will make as a member of the Conformis team." Denise Pedulla Prior to joining Conformis, Denise served as the General Counsel and Corporate Secreta

      3/14/22 4:30:00 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Conformis, Inc. Appoints James Paiva as its new Vice President of U.S. Marketing; Inducement Grant Reported

      BILLERICA, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that the Company has appointed James Paiva as its new Vice President, U.S. Marketing. "Conformis is pleased to welcome James Paiva as the new V.P. of U.S. Marketing. As we continue to advance our growth strategy, we are confident that James' extensive background in new product introductions and multi-channel marketing will help to strengthen Conformis brand recognition and position us to capitalize on anticipated growth in the ambulatory surgery center space," said Mark Augusti, President and Chief Executive Officer.  "I look forward to the contributions James will make as a member of Confo

      11/8/21 9:00:00 AM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Conformis Inc. (Amendment)

      SC 13G/A - Conformis Inc (0001305773) (Subject)

      7/10/23 5:14:02 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Conformis Inc. (Amendment)

      SC 13G/A - Conformis Inc (0001305773) (Subject)

      2/14/23 12:20:12 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Conformis Inc. (Amendment)

      SC 13G/A - Conformis Inc (0001305773) (Subject)

      2/13/23 10:56:02 AM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    SEC Filings

    See more
    • SEC Form 15-12G filed by Conformis Inc.

      15-12G - Conformis Inc (0001305773) (Filer)

      9/15/23 9:56:53 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form S-8 POS filed by Conformis Inc.

      S-8 POS - Conformis Inc (0001305773) (Filer)

      9/5/23 6:08:15 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form S-8 POS filed by Conformis Inc.

      S-8 POS - Conformis Inc (0001305773) (Filer)

      9/5/23 6:08:13 AM ET
      $CFMS
      Industrial Specialties
      Health Care